Genmab A/S (GMAB) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.093x

Based on the latest financial reports, Genmab A/S (GMAB) has a cash flow conversion efficiency ratio of 0.093x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr536.00 Million ≈ $83.86 Million USD) by net assets (Dkr5.75 Billion ≈ $899.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Genmab A/S - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how Genmab A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Genmab A/S balance sheet liabilities for a breakdown of total debt and financial obligations.

Genmab A/S Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genmab A/S ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Bank Polska Kasa Opieki SA
WAR:PEO
0.245x
Brookfield Infrastructure Partners L.P
TO:BIP-UN
0.058x
Annaly Capital Management, Inc.
NYSE:NLY
0.040x
Bank of Beijing Co Ltd
SHG:601169
-0.375x
Telkom Indonesia (Persero) Tbk PT
JK:TLKM
0.110x
Alamos Gold Inc
TO:AGI
0.064x
PTC Inc
NASDAQ:PTC
0.070x
Textron Inc
NYSE:TXT
0.089x

Annual Cash Flow Conversion Efficiency for Genmab A/S (2002–2024)

The table below shows the annual cash flow conversion efficiency of Genmab A/S from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Genmab A/S (GMAB) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Dkr36.70 Billion
≈ $5.74 Billion
Dkr7.77 Billion
≈ $1.22 Billion
0.212x -9.30%
2023-12-31 Dkr31.61 Billion
≈ $4.95 Billion
Dkr7.38 Billion
≈ $1.15 Billion
0.233x +62.82%
2022-12-31 Dkr27.28 Billion
≈ $4.27 Billion
Dkr3.91 Billion
≈ $612.06 Million
0.143x +42.85%
2021-12-31 Dkr22.20 Billion
≈ $3.47 Billion
Dkr2.23 Billion
≈ $348.59 Million
0.100x -70.16%
2020-12-31 Dkr19.12 Billion
≈ $2.99 Billion
Dkr6.43 Billion
≈ $1.01 Billion
0.336x +256.43%
2019-12-31 Dkr14.05 Billion
≈ $2.20 Billion
Dkr1.33 Billion
≈ $207.46 Million
0.094x -25.45%
2018-12-31 Dkr8.01 Billion
≈ $1.25 Billion
Dkr1.01 Billion
≈ $158.77 Million
0.127x -50.02%
2017-12-31 Dkr6.27 Billion
≈ $981.33 Million
Dkr1.59 Billion
≈ $248.61 Million
0.253x +273.12%
2016-12-31 Dkr4.83 Billion
≈ $755.17 Million
Dkr327.72 Million
≈ $51.27 Million
0.068x -23.99%
2015-12-31 Dkr3.49 Billion
≈ $545.52 Million
Dkr311.45 Million
≈ $48.73 Million
0.089x +36.87%
2014-12-31 Dkr2.03 Billion
≈ $318.07 Million
Dkr132.67 Million
≈ $20.76 Million
0.065x +133.63%
2013-12-31 Dkr659.52 Million
≈ $103.19 Million
Dkr-128.00 Million
≈ $-20.03 Million
-0.194x -204.86%
2012-12-31 Dkr383.19 Million
≈ $59.95 Million
Dkr70.92 Million
≈ $11.10 Million
0.185x +120.59%
2011-12-31 Dkr486.42 Million
≈ $76.10 Million
Dkr-437.23 Million
≈ $-68.41 Million
-0.899x -462.02%
2010-12-31 Dkr1.08 Billion
≈ $168.98 Million
Dkr268.17 Million
≈ $41.96 Million
0.248x +156.50%
2009-12-31 Dkr1.30 Billion
≈ $202.96 Million
Dkr-570.06 Million
≈ $-89.19 Million
-0.439x -87.36%
2008-12-31 Dkr2.19 Billion
≈ $342.42 Million
Dkr-513.33 Million
≈ $-80.31 Million
-0.235x -233.68%
2007-12-31 Dkr2.88 Billion
≈ $451.11 Million
Dkr505.90 Million
≈ $79.15 Million
0.175x +174.30%
2006-12-31 Dkr1.61 Billion
≈ $251.52 Million
Dkr-379.62 Million
≈ $-59.39 Million
-0.236x -26.62%
2005-12-31 Dkr1.12 Billion
≈ $175.04 Million
Dkr-208.64 Million
≈ $-32.64 Million
-0.186x +40.10%
2004-12-31 Dkr1.18 Billion
≈ $184.77 Million
Dkr-367.70 Million
≈ $-57.53 Million
-0.311x -11.87%
2003-12-31 Dkr1.09 Billion
≈ $169.98 Million
Dkr-302.36 Million
≈ $-47.31 Million
-0.278x -26.30%
2002-12-31 Dkr1.40 Billion
≈ $218.91 Million
Dkr-308.32 Million
≈ $-48.24 Million
-0.220x --

About Genmab A/S

CO:GMAB Denmark Biotechnology
Market Cap
$16.33 Billion
Dkr104.35 Billion DKK
Market Cap Rank
#1511 Global
#8 in Denmark
Share Price
Dkr1694.00
Change (1 day)
+0.24%
52-Week Range
Dkr1270.00 - Dkr2251.00
All Time High
Dkr3295.00
About

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more